尿激酶,脑出血 z-bo 2020-09-23 405

　　Recently, Chongqing Southwest Hospital discovered that after years of scientific research, the neurosurgery team of Southwest Hospital finally confirmed that urokinase plays a special role in the treatment of cerebral hemorrhage. The results of this scientific research were published in the internationally renowned "Journal of Neurosurgery". At present, in the minimally invasive treatment of cerebral hemorrhage, the most commonly used fibrinolytic agent is tissue plasminogen activator (tPA), which can quickly dissolve the "thrombosis" formed by brain congestion. And clean it up as soon as possible after the doctor removes it. However, studies have shown that this drug is expensive, which not only brings greater financial pressure to patients, but also tPA may cause delayed cerebral edema and nerve damage.

　　Urokinase project research leader, 973 project chief scientist Feng Hua and his team unexpectedly discovered in an academic exchange that some small hospitals and clinical research centers combine minimally invasive surgery with fibrinolysis. There are records of the use of urokinase, which has been used to eliminate cerebral hemorrhage, but there is a lack of relevant data. According to Fuka, Urokinase plus Minogen Activator (uPA) has been used in China for many years, mainly for thrombolytic treatment of thromboembolic diseases, such as acute generalized pulmonary embolism and myocardial infarction. However, in minimally invasive surgery, it is not the main fibrinolytic agent.

　　The research team realized that urokinase may focus on reducing brain hematoma and protecting brain nerve tissue during minimally invasive surgery. Based on this idea, Fuka and his team conducted specific research for more than two years.

　　"In this study, we used the classic "brain autologous blood injection" to simulate human cerebral hemorrhage, and used uPA and tPA as the brain minimally invasive surgical fibroid. The hematoma was removed. Although tPA and tPA were injected at the same time tPA can effectively reduce the occurrence of intracerebral hematoma, but uPA can more effectively reduce the cerebral edema around the hematoma and the tight binding protein of the blood-brain barrier and nerve function. It is protected, thereby increasing the success rate of surgery. Feng Hua said the research team Large animal test models and clinical trials will be conducted to further verify the safety and effectiveness of uPA in the treatment of cerebral hemorrhage. This finding is expected to be used by neurosurgery experts.